Abstract
Background: Secondary Cushing’s syndrome due to chronic use of exogenous corticosteroids is an endocrine disorder caused by prolonged exposure to these drugs, which are commonly used to treat various inflammatory and autoimmune diseases. One of its most serious complications is secondary adrenal insufficiency, which can occur following corticosteroid withdrawal syndrome (CWS). This syndrome arises when glucocorticoids are abruptly discontinued, leading to suppression of the hypothalamic-pituitary-adrenal (HPA) axis and, consequently, an acute reduction in endogenous cortisol production, potentially triggering an adrenal crisis.
Purpose: Provide information on the risks associated with the indiscriminate use of corticosteroids, their adverse health effects due to prolonged use, and the consequences of abruptly discontinuing these medications.
Case presentation: A patient who used glucocorticoids for a long time to manage chronic pain, subsequently developed exogenous Cushing's syndrome. After abrupt discontinuation of these medications, suppression of the HPA axis was evident and, consequently, AI.
Discussion and conclusion: It is estimated that Cushing’s syndrome due to exogenous corticosteroid use accounts for 70-90% of cases. Abrupt withdrawal of these drugs may lead to adrenal crisis secondary to corticosteroid withdrawal syndrome. In Colombia, the easy availability of glucocorticoids favors their inappropriate use; therefore, diagnosis should rely on a thorough medical history and laboratory evaluation when clinically suspected.
References
González Clavijo AM, Fierro Maya LF, Alvarez-Lozano MA, Moreno-Soler GA, Rodríguez-Paz S, Tarquino-Rincón D. Síndrome de Cushing exógeno de difícil diagnóstico. Acta Med Colomb [Internet]. 2020 [citado el 14 de julio de 2024];45(3):75–7. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-24482020000300075&lng=pt&tlng=es. https://doi.org/10.36104/amc.2020.1500
Savas M, Mehta S, Agrawal N, van Rossum EFC, Feelders RA. Approach to the patient: Diagnosis of Cushing syndrome. J Clin Endocrinol Metab [Internet]. 2022;107(11):3162–74. Disponible en: http://dx.doi.org/10.1210/clinem/dgac492
Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ [Internet]. 2021;374:n1380. Disponible en: http://dx.doi.org/10.1136/bmj.n1380
Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers [Internet]. 2021;7(1):19. Disponible en: http://dx.doi.org/10.1038/s41572-021-00252-7
Carroll TB, Findling JW. Cushing’s syndrome of nonpituitary causes. Curr Opin Endocrinol Diabetes Obes [Internet]. 2009;16(4):308–15. Disponible en: http://dx.doi.org/10.1097/MED.0b013e32832d8950
Martin-Grace J, Tomkins M, O’Reilly MW, Sherlock M. Iatrogenic adrenal insufficiency in adults. Nat Rev Endocrinol [Internet]. 2024;20(4):209–27. Disponible en: http://dx.doi.org/10.1038/s41574-023-00929-x
Bertholle-Gil J, Gil-Palmer A, Nicolau-Ramis J. Adrenal insufficiency secondary to topic clobetasol. Med Clin (Barc) [Internet]. 2019;154(8):324–5. Disponible en: http://dx.doi.org/10.1016/j.medcli.2019.03.026
Mateos Moreno L, Palacios García N, Estrada García FJ. Adrenal insufficiency in critical patients: New ethiopathogenic concepts and therapeutic implications. Endocrinol Diabetes Nutr [Internet]. 2017;64(10):557–63. Disponible en: http://dx.doi.org/10.1016/j.endinu.2017.09.004
Endocrine Society. Endo 2022. Meet the professor. Endocrine. Case management. From experts in endocrinology. Washington, DC: Endocrine Society; [Libro]. 2022. p. 30-38. [citado el 02 de Octubre de 2024]

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

